Clinical Trial Update: Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine [Phase 1]

View source ↗

Summary

A Phase 1 trial of the Heat Shock Protein Peptide Complex-96 (HSPPC-96) vaccine for glioblastoma and related CNS tumors was terminated. The study enrolled indic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Ependymoma
• Clear Cell Ependymoma
• Ependymoma
• Glioblastoma

Drugs mentioned

• Heat Shock Protein Peptide Complex-96 Vaccine (Heat shock protein peptide complex-96)

Snippet

Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago | Conditions: Glioblastoma Multiforme, Astrocytoma, Grade III | Phase 1 | Status: TERMINATED